Tags

Type your tag names separated by a space and hit enter

The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.
Antiviral Res. 2020 06; 178:104787.AR

Abstract

Although several clinical trials are now underway to test possible therapies, the worldwide response to the COVID-19 outbreak has been largely limited to monitoring/containment. We report here that Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activity in vitro, is an inhibitor of the causative virus (SARS-CoV-2), with a single addition to Vero-hSLAM cells 2 h post infection with SARS-CoV-2 able to effect ~5000-fold reduction in viral RNA at 48 h. Ivermectin therefore warrants further investigation for possible benefits in humans.

Links

Publisher Full Text
ncbi.nlm.nih.gov
linkinghub.elsevier.com
PMC Free PDF
Aggregator Full Text

Authors+Show Affiliations

Caly L
Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital, At the Peter Doherty Institute for Infection and Immunity, Victoria, 3000, Australia.
Druce JD
Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital, At the Peter Doherty Institute for Infection and Immunity, Victoria, 3000, Australia.
Catton MG
Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital, At the Peter Doherty Institute for Infection and Immunity, Victoria, 3000, Australia.
Jans DA
Biomedicine Discovery Institute, Monash University, Clayton, Vic, 3800, Australia.
Wagstaff KM
Biomedicine Discovery Institute, Monash University, Clayton, Vic, 3800, Australia. Electronic address: kylie.wagstaff@monash.edu.

MeSH

AnimalsAntiviral AgentsAustraliaBetacoronavirusCOVID-19Chlorocebus aethiopsCoronavirus InfectionsDrug ApprovalHumansIvermectinPandemicsPneumonia, ViralSARS-CoV-2Vero CellsVirus Replication

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

32251768

Clinical Trial Links

Ivermectin and Nitazoxanide Combination Therapy for COVID-19
Hydroxychloroquine and Nitazoxanide Combination Therapy for COVID-19
Hydroxychloroquine and Ivermectin for the Treatment of COVID-19 Infection
New Antiviral Drugs for Treatment of COVID-19
Efficacy of Ivermectin in COVID-19
Efficacy, Safety and Tolerability of Ivermectin in Subjects Infected With SARS-CoV-2 With or Without Symptoms
Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19
A Comparative Study on Ivermectin and Hydroxychloroquine on the COVID19 Patients in Bangladesh
Efficacy of Subcutaneous Ivermectin With or Without Zinc in COVID-19 Patients
Ivermectin to Prevent Hospitalizations in COVID-19
Safety and Efficacy of Ivermectin and Doxycycline in Treatment of Covid-19
Ivermectin in Adults With Severe COVID-19.
Ivermectin for Severe COVID-19 Management
Prophylaxis Covid-19 in Healthcare Agents by Intensive Treatment With Ivermectin and Iota-carrageenan
Study in COvid-19 Patients With iveRmectin (CORVETTE-01)

Citation

Caly, Leon, et al. "The FDA-approved Drug Ivermectin Inhibits the Replication of SARS-CoV-2 in Vitro." Antiviral Research, vol. 178, 2020, p. 104787.
Caly L, Druce JD, Catton MG, et al. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020;178:104787.
Caly, L., Druce, J. D., Catton, M. G., Jans, D. A., & Wagstaff, K. M. (2020). The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Research, 178, 104787. https://doi.org/10.1016/j.antiviral.2020.104787
Caly L, et al. The FDA-approved Drug Ivermectin Inhibits the Replication of SARS-CoV-2 in Vitro. Antiviral Res. 2020;178:104787. PubMed PMID: 32251768.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. AU - Caly,Leon, AU - Druce,Julian D, AU - Catton,Mike G, AU - Jans,David A, AU - Wagstaff,Kylie M, Y1 - 2020/04/03/ PY - 2020/03/18/received PY - 2020/03/27/revised PY - 2020/03/29/accepted PY - 2020/4/7/pubmed PY - 2020/7/7/medline PY - 2020/4/7/entrez SP - 104787 EP - 104787 JF - Antiviral research JO - Antiviral Res VL - 178 N2 - Although several clinical trials are now underway to test possible therapies, the worldwide response to the COVID-19 outbreak has been largely limited to monitoring/containment. We report here that Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activity in vitro, is an inhibitor of the causative virus (SARS-CoV-2), with a single addition to Vero-hSLAM cells 2 h post infection with SARS-CoV-2 able to effect ~5000-fold reduction in viral RNA at 48 h. Ivermectin therefore warrants further investigation for possible benefits in humans. SN - 1872-9096 UR - https://www.unboundmedicine.com/medline/citation/32251768/full_citation L2 - https://linkinghub.elsevier.com/retrieve/pii/S0166-3542(20)30201-1 DB - PRIME DP - Unbound Medicine ER -